Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Obicetrapib | Heterozygous familial hypercholesterolemia (HeFH) | Phase 3 | Dec 31, 2026 | — |
| Obicetrapib + ezetimibe | ASCVD and/or HeFH patients | Phase 3 | Dec 31, 2026 | Mgmt interest |
| Obicetrapib | ASCVD (Cardiovascular Outcomes) | Phase 3 | Mar 31, 2027 | Mgmt interest |
Upcoming milestones
Company profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Heterozygous familial hypercholesterolemia (HeFH)
Data readoutASCVD and/or HeFH patients
Data readout